Solexa Ltd

Pharmacogenomics. 2004 Jun;5(4):433-8. doi: 10.1517/14622416.5.4.433.


Solexa Ltd is developing an integrated system, based on a breakthrough single molecule sequencing technology, to address a US$2 billion market that is expected to grow exponentially alongside and as a consequence of further technological enhancements. The system, software and consumables will initially be sold to research organizations, pharmaceutical companies and diagnostic companies that will sequence large regions of genomic DNA, including whole genomes, at costs several orders of magnitude below current levels. Solexa expects to launch its first product in 2006, and as it continues to make time and cost efficiencies, additional products will be launched into the expanding markets that will have broad applications in basic research through to healthcare management.

MeSH terms

  • Biotechnology / methods*
  • Biotechnology / trends
  • Genome, Human*
  • Humans
  • Oligonucleotide Array Sequence Analysis / methods*
  • Oligonucleotide Array Sequence Analysis / trends
  • Pharmacogenetics / methods
  • Pharmacogenetics / trends
  • Sequence Analysis, DNA / methods
  • Sequence Analysis, DNA / trends